In a groundbreaking achievement, researchers at Penn Med and CHOP have successfully treated an infant with the world’s first personalized gene-editing therapy. This innovative method can be easily replicated to correct mutations in DNA, offering hope for patients with inherited disorders. By modifying only the CRISPR instructions that target the mutated site, pharmaceutical companies can potentially bypass the need for individual FDA approvals, revolutionizing the way personalized cures are developed and administered. This advancement opens up new possibilities in gene therapy for inherited disorders, paving the way for more efficient and accessible treatments in the future.
Read more about this — here
